You are here:

bevacizumab (Avastin)

Advice

following a second resubmission assessed under the end of life and orphan equivalent process

bevacizumab (Avastin®) is accepted for restricted use within NHS Scotland.

Indication under review: In combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.

SMC restriction: In patients with FIGO stage IV disease

Addition of bevacizumab to standard chemotherapy with carboplatin and paclitaxel increased progression-free survival.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
 

Drug Details

Drug Name: bevacizumab (Avastin)
SMC Drug ID: 806/12
Manufacturer: Roche
Indication: In combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 9 November 2015

Archived Advice

Resubmission 12 January 2015
Full submission 8 October 2012

Back